Giuseppe Gritti
Consultant hematologist, Hematology and BMT Unit, Department of Hematology and Oncology · ASST Papa Giovanni XXIII
https://researchid.co/g.gritti
@asst-pg23.it
66Scopus Publications
Recent Scopus Publications
- Correction: Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-up (Blood Cancer Journal, (2025), 15, 1, (129), 10.1038/s41408-025-01329-2)
- Pirtobrutinib in relapsed or refractory mantle cell lymphoma: outcomes from the compassionate use program in Italy
- Polatuzumab Vedotin and Glofitamab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the Compassionate Use Program in Italy
- Association of PET4 response with outcomes of BV-CHP vs CHOP in the ECHELON-2 trial in CD30+ peripheral T-cell lymphoma
- Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib/II Trial
Links
- ORCID https://orcid.org/0000-0002-6789-5123
- Scopus https://www.scopus.com/authid/detail.uri?authorId=7006677850